Evotec SE
EVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Evotec SE (EVO) is listed under Drug Manufacturers - Specialty & Generic. The $1.05B market capitalization puts EVO squarely in small-cap range for its industry. It operates in two segments, Shared R&D and Just Evotec Biologics.
Market Cap
$1.05B
Beta
1.30
P/E (TTM)
—
P/E (Fwd)
-15.58
EPS (TTM)
$-0.65
EPS (Fwd)
$-0.19
ROE
-24.1%
ROA
-3.1%
Cash
$444.8M
Total Debt
$387.5M
Free CF
$98.6M
52W Change
-25.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $444.8M in cash comfortably exceeding the $387.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $98.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -24.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $751.4M (2022) to $788.4M (2025).
Investors considering Evotec SE should weigh the typical risks associated with EVO's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing EVO.